|Bid||8,451.00 x 0|
|Ask||8,453.00 x 0|
|Day's range||8,430.00 - 8,577.00|
|52-week range||5,871.00 - 9,537.09|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||51.74|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||2.16 (2.57%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||78.83|
AstraZeneca PLC's (LON:AZN) price-to-earnings (or "P/E") ratio of 67.7x might make it look like a strong sell right...
New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.
Japan plans to buy AstraZeneca Plc's <AZN.L> experimental COVID-19 vaccine and fund a local company to manufacture Novavax's <NVAX.O> vaccine candidate, ramping up its stockpile plan as it battles surging infections. Japan will order 120 million doses of the experimental vaccine developed by the British pharmaceutical company, beginning with 30 million doses by March next year. Separately, Takeda Pharmaceutical <4502.T> said on Friday it would manufacture and sell up to 250 million doses of Novavax's COVID-19 vaccine candidate every year in Japan, with funding support from the government.